Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 2/20 | 0.50 |
| ▸ | TDP2 | O95551 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | PTPRC | P08575 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL244695 | 1.00 | APAF1 (0.50) | APAF1TDP2MCL1BCL2P2RX7 | |
| Hydrochloric Acid SCHEMBL16369796 | 0.98 | APAF1 (0.48) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL11352933 | 0.96 | APAF1 (0.46) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL3465719 | 0.96 | APAF1 (0.46) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL8190848 | 0.89 | APAF1 (0.64) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL7120454 | 0.82 | S100A4 (0.41) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL27981640 | 0.82 | APAF1 (0.41) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL19230417 | 0.81 | ALDH1A1 (0.52) | APAF1TDP2MCL1BCL2CES2 | |
| SCHEMBL29364188 | 0.78 | MEN1 (0.56) | APAF1TDP2MCL1BCL2CES2 | |
| SCHEMBL354514 | 0.78 | MEN1 (0.56) | APAF1TDP2MCL1BCL2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| US-20250277045-A1 | DEVELOPMENT AND APPLICATION OF T-CELL ENGAGER THERAPEUTIC AGENT | KEYMED BIOSCIENCES CO.,LTD (CN) | 2025-09-04 | — | — | US | claimed |
| US-20240247072-A1 | DEVELOPMENT AND USE OF FUNCTION-ENHANCED ANTIBODY BLOCKING AGENT | Keymed Biosciences Co., Ltd (CN) | 2024-07-25 | — | — | US | claimed |
| US-20240002540-A1 | BISPECIFIC ANTIBODY AND USE THEREOF | KEYMED BIOSCIENCES CO.,LTD (CN) | 2024-01-04 | — | — | US | claimed |
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | ILAB (KR) | 2023-12-26 | — | — | US | claimed |
| EP-4273169-A1 | DEVELOPMENT AND USE OF FUNCTION-ENHANCED ANTIBODY BLOCKING AGENT | Keymed Biosciences Co.,Ltd. (CN) | 2023-11-08 | — | — | EP | claimed |
| EP-4257607-A1 | DEVELOPMENT AND APPLICATION OF T-CELL ENGAGER THERAPEUTIC AGENT | Keymed Biosciences Co.,Ltd. (CN) | 2023-10-11 | — | — | EP | claimed |
| EP-4249514-A1 | BISPECIFIC ANTIBODY AND USE THEREOF | Keymed Biosciences Co.,Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2023-03-30 | — | — | US | claimed |
| US-12630652-B2 | Bispecific antibody and use thereof | KEYMED BIOSCIENCES (CHENGDU) CO., LTD (CN) | 2026-05-19 | — | — | US | disclosed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-121673250-B | Polyamino cationic lipids containing carbamate structures, compositions comprising same and uses | 北京悦康科创医药科技股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4667004-A1 | LIPID COMPOSITION TARGETING ANTIGEN-PRESENTING CELLS AND USE THEREOF | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-12497435-B2 | Multimerization of IL-15/IL-15R-alpha-fc complexes to enhance immunotherapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-16 | — | — | US | disclosed |
| CN-113831834-B | Ultraviolet-proof film and preparation method thereof | 江苏东科电子科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20220227885-A1 | METHODS FOR DNA-DEPENDING TARGETING OF A CELL PERMEANT ANTIBODY | YALE UNIVERSITY (US) | 2022-07-21 | — | — | US | disclosed |
| CN-114616250-A | CD8 binding agents and uses thereof | 豪夫迈·罗氏有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-11306141-B2 | Antibody against human DLK1 and use thereof | Y-Biologics Inc. (KR) | 2022-04-19 | — | — | US | disclosed |
| WO-2022072762-A1 | COMBINATION OF ANTIBODIES FOR TREATING CANCER WITH REDUCED CYTOKINE RELEASE SYNDROME | REGENERON PHARMACEUTICALS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20220106375-A1 | MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | TNF, NFKBIA, TRAF6 | APAF1 1971/4885TDP2 4337/4885MCL1 3398/4885 |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | TNF, NFKBIA, TRAF6 | APAF1 1971/4885TDP2 4337/4885MCL1 3398/4885 |
| US-12630652-B2 | Bispecific antibody and use thereof | CD2, CD4, SETD1B | APAF1 2903/4885TDP2 1305/4885MCL1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.